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Abstract: Unintended pregnancy is a global reproductive health problem. Emergency 
  contraception (EC) provides women with a safe means of preventing unwanted pregnancies after 
having unprotected intercourse. While 1.5 mg of levonorgestrel (LNG) as a single dose or in 
2 doses with 12 hours apart is the currently gold standard EC regimen, a single dose of 30 mg 
ulipristal acetate (UPA) has recently been proposed for EC use up to 120 hours of unprotected 
intercourse with similar side effect profiles as LNG. The main mechanism of action of both LNG 
and UPA for EC is delaying or inhibiting ovulation. However, the ‘window of effect’ for LNG EC 
seems to be rather narrow, beginning after selection of the dominant follicular and ending when 
luteinizing hormone peak begins to rise, whereas UPA appears to have a direct inhibitory effect 
on follicular rupture which allows it to be also effective even when administered shortly before 
ovulation, a time period when use of LNG is no longer effective. These experimental findings 
are in line with results from a series of clinical trials conducted recently which demonstrate that 
UPA seems to have higher EC efficacy compared to LNG. This review summarizes some of the 
data available on UPA used after unprotected intercourse with the purpose to provide evidence 
that UPA, a new type of second-generation progesterone receptor modulator, represents a new 
evolutionary step in EC treatment.
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Introduction
Despite the availability of highly effective methods of contraception, a great number 
of pregnancies are unintended. Many women who experience an unintended pregnancy 
have become pregnant as a result of either lacking of contraceptives or contraceptive 
failure. Emergency contraception (EC) is defined as the use of any drug or device after 
unprotected intercourse to prevent an unwanted pregnancy. Although the situations that 
lead to contraceptive failure are diverse, most women know the reasons why they got 
pregnant (such as, forgetting the pill, condom slippage) and could thus have used EC 
to prevent the pregnancy.1 Despite of rapidly increasing use, EC is still underutilized 
worldwide. It has been estimated that millions of unwanted pregnancies could be 
avoided if EC were widely accessible and properly used,2 although its impact on the 
population seems questionable.3,4 Today levonorgestrel (LNG) is the gold standard for 
oral EC. Recently, a new type of second generation progesterone receptor modulator, 
ulipristal acetate (UPA), has emerged which represents a new evolutionary step in 
EC treatment. UPA EC has been shown to be associated with a lower pregnancy rate 
compared to LNG EC. This review will summarize some of the clinical data available 
on UPA when used for preventing pregnancy after unprotected intercourse.International Journal of Women’s Health 2010:2 54
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Available methods
Several approaches to EC have been described. Although the 
copper-bearing intrauterine device (IUD) is the most effec-
tive EC method, its widespread use is limited due to logistic 
and medical reasons. In the late 1970s Yuzpe introduced a 
regimen consisting of 0.1 mg ethinylestradiol and 0.5 mg 
LNG, given within 72 hours of the intercourse and repeated 
after 12 hours.5 The Yuzpe regimen was the most commonly 
used EC method until the late 1990s when it started to be 
replaced by the administration of LNG. Treatment with 
LNG 0.75 mg, repeated after 12 hours or as a single dose of 
1.5 mg, was shown to be associated with lower rate of side 
effects and higher efficacy than the Yuzpe regimen.6–8 The 
efficacy of both regimens decreased with treatment delay. 
In a subsequent study, the efficacy of a single dose of 10 mg 
mifepristone was compared to LNG 1.5 mg either in a single 
dose or in 2 doses 12 hours apart.9 Pregnancy rates did not 
differ between mifepristone and LNG treatment in divided or 
single doses when taken within 5 days of unprotected inter-
course. Side effects were mild and similar between treatment 
groups. The efficacy of mifepristone when used for EC has 
been shown to be dose dependent.10 Although mifepristone 
(mid or high doses) has higher efficacy than LNG,10 the 
potential for mifepristone EC is limited due to social and 
political reasons since it can be used and is available as an 
abortifacient if combined with a prostaglandin analogue. To 
date, mifepristone in low doses (10, 25 or 50 mg) for EC is 
available only in China.
Following these studies and until now, LNG 1.5 mg as 
a single dose taken as soon as possible and within 72 hours 
of unprotected intercourse has become the recommended 
regimen for oral EC pill. Although EC with 1.5 mg LNG has 
contributed to the prevention of unwanted pregnancies, it has 
limitations in terms of efficacy which drops significantly with 
the time elapsed since unprotected intercourse. Pregnancy 
rates with LNG EC in the first 24 hours are approximately 
1.5%, but increase to 2.6% during the period of 48 to 72 hours 
after exposure.7,9,11,12
Ulipristal acetate (UPA)
Ulipristal acetate, also referred to as CDB-2914 or 
VA2914, is a novel orally active selective progesterone 
receptor modulator (SPRM) with the chemical name 17α-
  acetoxy-11β-[4-N,N-dimethylaminophenyl-19-norpregna-
4,9-diene-3, 20-dione.13–16 It is a white to yellow crystal 
powder, which is insoluble in water (3 mg/100 mL) with the 
molecular weight of 475.6. The molecular formula of UPA 
is C30H37NO4 (Pubchem, CID: 130904).
Ulipristal acetate is a derivative of 19-norprogesterone 
and was developed to have enhanced specificity for proges-
terone receptor. Pre-clinical studies indicate that UPA binds 
to human progesterone, glucocorticoid and androgen recep-
tors at approximately 6, 1.5 and 0.2 times the affinity of the 
endogenous ligands and shows in vivo anti-glucocorticoid and 
anti-androgen activity at doses approximately 50-fold greater 
than those needed for anti-progestin effect. Its binding and 
antagonist potency with respect to the glucocorticoid recep-
tor is significantly reduced compared to that of mifepristone, 
indicating that UPA belongs to a new type of dissociated pro-
gesterone receptor modulators that have reduced antiglucor-
ticoid activity.13,15–17 The chemical structure of progesterone, 
LNG and UPA is depicted in Figure 1.
The pharmacodynamic properties of UPA in humans 
reflect the mixed progesterone agonistic/antagonistic profile 
of the molecule.17 In addition to development for an EC use, 
UPA is also being developed in other indications, including 
treatment of uterine fibroids.18
Following oral administration of a single 30 mg dose, 
UPA is rapidly absorbed, with a peak plasma concentration 
of 176 ± 89 ng/mL occurring approximately 0.5 to 3 hours 
after ingestion, depending on whether the drug is taken during 
the fasting state or after a meal. Doses of unmicronized 1, 
Figure 1 The chemical structures for progesterone, levonorgestrel and ulipristal acetate.
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10 and 50 mg UPA exhibit proportional increases in peak 
serum levels, but serum levels from higher doses, 100 and 
200 mg, are not dose-dependent, suggesting saturation of 
carrier sites.17
Absorption of UPA is pH-dependent. High binding 
(98%) occurs to plasma proteins. The compound is exten-
sively metabolized by cytochrome P450 3A4 (CYP3A4) 
in the liver, and the principal metabolites formed are the 
mono- and di-demethylated derivatives, of which the former, 
3877A, is pharmacologically active. The terminal half-life 
in plasma is 32.4 ± 6.3 hours (data on file).
In vitro studies have shown that CYP3A4 is primarily 
responsible for the metabolism of UPA (SPC). Although 
specific drug–drug interaction studies have not been per-
formed, it is possible that inducers of CYP3A4, eg, rifampin, 
dexamethasone, St. John’s wort, and certain anticonvulsants 
(phenytoin, phenobarbital, carbamazepine), may induce the 
metabolism of UPA and cause lowered plasma levels. Further-
more, inhibitors of CYP3A4, eg, the HIV protease inhibitors, 
itraconazole, erythromycin, and grapefruit juice, may inhibit 
the metabolism of UPA and cause increased plasma levels.
The fertile window
It is only during a limited period, from 5 days before to 1 day 
after ovulation, that unprotected intercourse may result in a 
pregnancy.19–21 However, in assessing EC efficacy, the variabil-
ity of ovulation has to be taken into account. It was calculated 
that the possibility of late ovulation produces a persistent risk 
of pregnancy even into the sixth week of the cycle.22 A major 
discrepancy between women’s self-report of stage of the 
menstrual cycle and the dating calculation based on endocrine 
data was shown in a clinical trial on the effectiveness of EC.23 
Studies have also shown that the frequency of intercourse rose 
during the follicular phase, peaking at ovulation and declin-
ing abruptly thereafter. The 6 consecutive days with most 
frequent intercourse corresponded with the 6 fertile days of 
the menstrual cycle.24 Therefore, it is likely that in a popula-
tion of women administered EC, a significant proportion are 
at least at some risk of pregnancy. Therefore, EC should be 
recommended at any time during the cycle after any act of 
unprotected intercourse or contraceptive accident.
Methods to determine EC efficacy
Pearl index for measuring contraceptive efficacy cannot 
be used for evaluating the efficacy of an EC. In the trials, 
women who presented within the defined time window 
after unprotected intercourse were administered EC, and 
they were followed-up to determine whether or not they 
became pregnant. Women included in these studies had, by 
definition, varying degrees of pregnancy risk, depending on 
how close the index act of intercourse occurred to the fertile 
window in the cycle (the 6 days leading up to and including 
the day of ovulation as discussed above) and how fertile 
they (and their partners) were, depending on age and other 
physiological characteristics. In addition, it is extremely dif-
ficult to predict with sufficient accuracy where a woman is 
in her menstrual cycle at the time of unprotected intercourse. 
Therefore 2 complementary parameters to provide estimates 
of the EC efficacy have been proposed:
i)  The first is the pregnancy rate, defined as the number 
of pregnancies observed at follow-up divided by the 
total number of women exposed to EC in a given trial. 
Pregnancy rate is an objective measure that includes all 
subjects exposed to EC but does not take into account 
their degree of risk of pregnancy and therefore poten-
tially overestimates EC efficacy, even though studies 
have shown that the frequency of intercourse in the 
menstrual cycle peaks during the fertile window, render-
ing it likely that in a population of women administered 
EC, a significant proportion are at least at some risk 
of pregnancy.24 When measured in large populations 
of presumably fertile women (women aged 35 with 
regular menstrual cycles), the pregnancy rate is therefore 
a fairly good estimate of the overall risk of pregnancy 
after EC intake.
ii)  The second is prevented fraction (contraceptive effective-
ness), defined as one minus the number of pregnancies 
observed divided by the number of pregnancies expected 
in the absence of EC treatment (1 – Pobs/Pexp). It measures 
the proportion of pregnancies avoided by EC treatment. 
The number of expected pregnancies is determined by 
assigning a known conception probability to each patient, 
according to the cycle day of intercourse relative to 
  ovulation.19,21 This calculation requires accurate informa-
tion for each woman included in the trial about the date 
of her last menstrual period. The length of luteal phase 
being a constant 14 days, the date of expected ovulation 
can be estimated assuming that the women in the study 
have regular menstrual cycles of a known length and that 
she correctly remembers her last menstrual period.
Mechanisms of action of EC pills
Introduction of EC pills in many countries has generated 
much controversy and litigation. One of the main barriers 
to widespread use of EC around the world is the confusion 
about potential mechanisms of action, such as concern that International Journal of Women’s Health 2010:2 56
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EC might impair implantation or disrupt an implanted fetus. 
Emergency contraception is also frequently confused with 
induced abortion. In many developing countries, the lack 
of knowledge about and access to EC may result in women 
resorting to unsafe abortions, which contribute significantly 
to maternal mortality and morbidity. Therefore adequate 
information on the mechanism of action of EC is crucial.
LNG
If administered at least 2 days prior to the luteinizing hormone 
(LH) surge, LNG causes either a delay or an inhibition of the 
LH surge, therefore delays or inhibits ovulation in women.25–28 
However, if given when LH has already started to rise, LNG 
cannot prevent ovulation.28,29 Furthermore, LNG in a regi-
men used for EC does not affect endometrial development 
or progesterone level.25,27 Human embryo implantation when 
studied in vitro is unaffected by LNG.30 Animal studies con-
firm that LNG does not affect fertilization or implantation.31,32 
These experimental findings are in line with the clinical data 
on LNG EC.23 In this clinical trial, 99 women were recruited 
at the time they presented with a request for EC and the 
effectiveness of EC pill when taken before and after ovulation 
was determined. A blood sample was taken immediately prior 
to ingestion of LNG 1.5 mg in a single dose for estimation 
of serum LH, estradiol and progesterone levels to calculate 
the day of ovulation. Three women became pregnant despite 
taking LNG (pregnancy rate, 3.0%). All three women who 
became pregnant had unprotected intercourse between 
Days −1 and 0 and took the LNG pill on Day +2, based on 
endocrine data. Day 0 was taken as ovulation day. Among 
17 women who had intercourse in the fertile period of the 
cycle and took the LNG pill after ovulation occurred (on Days 
+1 to +2), 3 or 4 pregnancies could have been expected and 
three were observed. Among 34 women who had intercourse 
on Days −5 to −2 of the fertile period and took the pill before 
or on the day of ovulation, four pregnancies could have been 
expected, but none were observed. Taken together an increas-
ing amount of data support the concept that LNG EC has no 
effect on post-ovulation events. Furthermore pregnancies 
occurring due to unprotected intercourse during the window 
when LNG EC lacks efficacy (after LH has started to rise until 
the day after ovulation or at the time of implantation) do not 
show any adverse effects from LNG exposure.33,34
UPA
Progesterone plays a key role during ovulation. Mice lacking 
progesterone receptor gene fail to ovulate due to a defect 
in follicular rupture.35 To identify pathways that modulate 
ovulation, gene expression profiling was performed using 
ovaries from mice subjected to gonadotropin-induced 
superovulation in the presence and in the absence of UPA. 
Prominent among the genes that were down-regulated in 
response to UPA was endothelin-2, a potent vasoactive 
molecule. Endothelin-2 mRNA was transiently induced in 
mural granulosa cells of the preovulatory follicles immedi-
ately preceding ovulation. This induction was absent in the 
ovaries of progesterone receptor null mice. Furthermore, 
mice treated with an endothelin selective antagonists of 
endothelin receptor-B exhibited a dramatic (85%) decline 
in the number of released oocytes.36
The biological effects of UPA vary according to the 
time of the menstrual cycle that the drug is given and the 
doses. Singles doses of UPA administered during the mid 
follicular phase suppress leading follicle growth, causing a 
dose-dependent delay in folliculogenesis and suppression of 
plasma estradiol. At higher does, a new leading follicle is 
often recruited.17,37 In a series of clinical trials the effect of 
UPA at different follicular diameters and in relation to the 
LH peak and ovulation was studied.38 When given prior to 
the LH rise, UPA inhibited 100% of follicular ruptures. When 
the size of the leading follicle was at least 18 mm, follicular 
rupture failed to occur within the 5 and 6 days following UPA 
treatment in 20 (59%) and 15 (44%) subjects respectively. 
Even on the day of the LH peak UPA could delay ovulation 
for 24 to 48 hours after administration. Taken together these 
studies demonstrate that UPA may have a direct inhibitory 
effect on follicular rupture. This allows UPA to be effective 
even when administered immediately before ovulation when 
LH has already started to rise, a time when use of LNG or 
Yuzpe is too late for ovulation inhibition (Figure 2).
In a study comparing early luteal phase treatement with pla-
cebo, 10, 50 or 100 mg unmicronized UPA, a significant delay 
in endometrial maturation was seen in the 50 and 100 mg groups 
compared to the placebo and the 10 mg group upon biopsy 4 to 
6 days after ovulation.17,37,39 Treatment with UPA resulted in a 
significant dose-dependent decrease in endometrial thickness 
as well as an increase in glandular P receptors.39
On average, UPA tends to lengthen the menstrual cycle by 
approximately 1 to 2 days although the amount of delay varies 
with timing in the menstrual cycle and dose. Women who 
received 50 mg unmicronized UPA experienced an average 
of 2 to 3 days delay in menses. This delay was dependent on 
when in the menstrual cycle the drug was taken, with the least 
effect occurring at about mid-cycle. Median values reflect 
a menses delay of 1 to 3 days when drug is taken during 
the follicular phase, little or no effect on cycle length when International Journal of Women’s Health 2010:2 57
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taken in the periovulatory period or the early to mid-luteal 
phase, and a tendency to delay menses when taken in the 
late luteal phase. However, 200 mg taken at the mid-luteal 
phase induced early menses, indicating that the changes in 
menstrual cycle length are likely to be dose-dependent.17
Mifepristone
The effect of mifepristone is well known to be depend on time 
of treatment during the menstrual cycle and the dose given. 
A variety of regimens with a single dose as low as 10 mg have 
been shown to interrupt follicle development and thus delay or 
inhibit ovulation.27,40–42 While higher doses affect endometrial 
receptivity and prevent implantation,30,43–45 10 mg mifepristone 
has little or no effect on the endometrium.27
Efficacy of UPA
A randomized controlled double-blinded phase II trial 
comparing the efficacy of 50 mg unmicronized UPA with 
LNG (0.75 mg twice) used within 72 hours of intercourse 
which was designed as a non-inferiority study included 
1549 women.46 A 50 mg unmicronized capsule of UPA is 
pharmacokinetically equal to 30 mg micronized drug sub-
stance formulated in a tablet (data on file). This trial showed 
that UPA was indeed statistically non-inferior to LNG (non-
inferiority margin of 2%). In addition, the results showed a 
trend towards higher efficacy of UPA in comparison to LNG. 
Of particular importance, the results showed that while the 
efficacy of LNG tended to be lower on the third day (48 
to 72 hours after intercourse) than the efficacy when used 
within 48 hours (as expected from previous trials with LNG), 
this was not the case in the women treated with UPA. Thus, 
a sustained efficacy of UPA was demonstrated up to 72 hours 
after unprotected intercourse whereas efficacy with LNG 
decreased over time.46 Pregnancy rates in the two groups were 
0.9% (95% confidence interval [CI] 0.2% to 1.6%) and 1.7% 
(95% CI 0.8% to 2.6%), respectively. The difference between 
treatments of –0.8%, with an upper limit of the 97.5% one-
tailed CI of 0.77%, was statistically non-inferior. When cal-
culating the contraceptive effectiveness (prevented fraction) 
of UPA and LNG, women treated with UPA experienced an 
85% reduction in the number of pregnancies whereas LNG 
users had a reduction of 69%.
A more recent phase III, non-inferiority trial con-
firmed the efficacy of UPA for EC up to 120 hours of 
unprotected intercourse.47 In this study, women presenting 
for EC within 120 hours of unprotected intercourse were 
randomized to be given a single dose of either 30 mg UPA 
or 1.5 mg LNG. A total of 1899 women were evaluated 
for efficacy. Pregnancy rates were 1.8% (95% CI 1.0% 
to .0%) for UPA and 2.6% (95% CI 1.7% to 3.9%) for 
LNG with an odds ratio (OR) (UPA versus LNG) of 0.57 
(95% CI 0.29 to 1.09).
The efficacy of a 30 mg UPA up to 120 hours after unpro-
tected intercourse was also evaluated in a phase III open-
label clinical trial.48 Only women who presented between 
48 hours and 120 hours after unprotected intercourse were 
eligible. The observed pregnancy rate following intake of 
UPA was 2.1% (95% CI 1.4% to 3.1%), which was statisti-
cally inferior to both estimated pregnancy rate of 5.5% and 
a predefined clinical irrelevance threshold. In addition, 
analysis trend did not reveal any increase of pregnancy rate 
over time up to 120 hours. There were no significant safety 
issues.
The databases from the two randomized controlled 
trials comparing UPA with LNG EC (n = 1549 women 
treated 72 hours after unprotected intercourse plus 
1899 women treated 120 hours) were merged in a 
meta-analysis including the primary efficacy popula-
tions defined in each study.47 Comparisons were done 
for different time windows of treatment in relation to 
unprotected intercourse. In analysis of the total 3445 
women it appeared that UPA was statistically superior to 
LNG for use within 120 hours (OR 0.55, 95% CI 0.32 to 
0.93). Moreover, UPA was statistically superior to LNG 
for intake within 24 hours of intercourse (n = 1184) with 
an OR of 0.35 (95% CI 0.11 to 0.93). The meta-analysis 
provides evidence that UPA is statistically more effective 
than LNG for early as well as late use of EC.
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Figure 2 Proportion of cycles without follicular rupture within the 5-day period 
following administration of emergency contraceptive pills with a follicular diameter 
of 18 mm. (UPA: ulipristal acetate, 30 mg; LNG: levonorgestrel, 1.5 mg in a single 
dose).
aData from Croxatto et al38; bData from Croxatto et al28 and Massai et al29; cData 
from Croxatto et al.53International Journal of Women’s Health 2010:2 58
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Bleeding profiles and  
adverse events
In the phase II randomized controlled trial comparing UPA to 
LNG, menstrual periods after the use of UPA or LNG were of 
normal duration and intensity.46 A reduction of 4 to 19 days 
in the menstrual interval during the treatment cycle occurred 
in 25% of LNG users and 17% of UPA users (P  0.001). On 
average, post-treatment cycle length was 2.6 days longer than 
anticipated date with UPA and 2.1 days shorter with LNG. 
While a shortening of the cycle may be the result of an inhibi-
tion of ovulation, a delay in menses subsequent to treatment 
with UPA is in line with a postponement of ovulation which is 
one important mechanism of action of this treatment. In addi-
tion, LNG users exhibited shortening of cycle length if the pill 
was taken in the proliferative phase, less shortening if taken at 
ovulation or in the early secretory phase and lengthening of the 
cycle when administered in the mid to late secretory phase. In 
contrast, no such trend was found between the different cycle 
phases for women who took UPA.46
Adverse events were mainly mild or moderate, short-
  lasting, self-limiting and similar with both EC pills. The most 
frequently observed side effects included lower abdominal 
pain, nausea, and headache.
Pregnancy and breast feeding
Ulipristal acetate in a single 30 mg dose has been shown to be 
safe and effective for EC in clinical studies prior to registra-
tion in Europe. A single dose of 30 mg UPA for EC (ellaOne®; 
HRA-Pharma, Paris, France) was approved by European Medi-
cines Agency (EMEA) in May 2009. So far only very few preg-
nancies have been exposed to UPA. Collection of further data 
is therefore needed. In an agreement between the EMEA and 
the market authorization holder, HRA-Pharma, a registry has 
been created to collect information on any pregnancy exposed 
to UPA, for example an unrecognized pregnancy before intake 
or as a result of treatment failure. The goal is to collect all data 
about pregnancy outcomes in women exposed to UPA.
So far it is unknown whether UPA is excreted in human 
milk as studies are lacking. As UPA is a lipophilic compound 
it may theoretically be excreted in human milk. Therefore, until 
more data is available breast-feeding is not recommended in 
the 36 hours following UPA intake. For LNG the correspond-
ing recommendation is to avoid breast-feeding for at least 
8 hours but not more than 24 hours after LNG intake.49
Posology
The approved treatment consists of 1 tablet of 30 mg UPA 
to be administered orally as soon as possible and no later 
than 120 hours (5 days) after unprotected intercourse. 
The tablet can be taken with or without food. Based 
on the pharmacokinetics it is recommended that if vomit-
ing occurs within 3 hours of UPA intake, another tablet 
should be taken. Pregnancy should be excluded before 
UPA is administered. Contraindications to UPA are similar 
to those of LNG-EC and include hypersensitivity to the 
active substance or any of the constituents and pregnancy 
(SMPC ellaOne®).
Interactions
Since UPA binds the progesterone receptor with high affinity, 
it may interfere with the action of progestogen-containing 
drugs. The data on combined action of UPA and LNG used 
for EC is so far unavailable. Supplementary administration 
of a SPRM improved bleeding patterns in women using 
progestogen-only pill (POP) regimen50 or subdermal contra-
ceptive implants releasing LNG (Norplant).51 The improve-
ment in bleeding pattern could be either by a direct effect of 
antiprogestin on the endometrium, as suggested by the effect 
on steroid receptor expression, or by inducing ovulation.52 
An increased ovulation rate may jeopardize contraception, 
Therefore, theorectically, concomitant use of UPA with LNG 
EC is not recommended. Furthermore, at least theoretical, 
the effectiveness of combined hormonal contraceptives 
and progestin only contraceptive may be reduced by UPA. 
Back-up barrier methods should be recommended for women 
relying on any form of hormonal contraceptives until her 
next menses.
Ulipristal acetate is metabolized by CYP3A4 in vitro and 
its absorption is pH-dependent. No specific drug interaction 
studies have been performed in vivo. However, CYP3A4 
inducers (eg, rifampicin, phenytoin, phenobarbital, carbam-
azepine, ritonavir, St. John’s wort) may theoretically reduce 
plasma concentrations of UPA and result in a decrease in 
efficacy. Concomitant use is therefore not recommended. 
Enzyme induction wears off slowly and effects on the 
plasma concentrations of UPA may occur even if a woman 
has stopped taking an enzyme inducer within the previous 
2 to 3 weeks.
Concomitant administration of medicinal products that 
increase gastric pH (eg, proton pump inhibitors, antacids 
and H2-receptor antagonists) may reduce plasma concen-
trations of UPA and may result in a decrease in efficacy. 
Concomitant use is therefore not recommended. However 
food interaction studies show that UPA can be taken with 
or without food.International Journal of Women’s Health 2010:2 59
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Conclusion and recommendations
Emergency contraception is the only method that women 
can use after having sexual intercourse without contraceptive 
protection to avoid becoming pregnant. It could be a powerful 
means to prevent unwanted pregnancies if widely available 
and acceptable.
UPA is a first-in-class progesterone receptor modulator 
specifically developed for EC. It has been demonstrated to 
be highly efficacious versus LNG for intake within 24 hours 
as well as for intake up to 72 hours after unprotected inter-
course. Furthermore, UPA maintains its efficacy up to 5 days 
after unprotected intercourse, matching the survival time of 
sperms. UPA 30 mg is as well-tolerated as LNG. Therefore 
UPA represents a veritable breakthrough in emergency 
contraceptive technology with a clear-cut medical advantage 
over LNG.
Although the main mechanism of action of both LNG 
and UPA is preventing follicular rupture and ovulation 
  (Figure 3), the ‘window of effect’ for LNG seems to be 
rather narrow, beginning after selection of the dominant 
follicle, and ending when LH begins to rise. In contrast, 
UPA has been demonstrated to have a direct inhibitory effect 
on follicular rupture. This allows UPA to be effective even 
when administered shortly before ovulation when the LH 
surge has already started to rise, a time period when use of 
LNG is no longer effective. The differences in mechanisms 
of action explain the higher efficacy demonstrated for UPA 
to prevent pregnancy for both early and late use of EC. 
UPA may not be the first line EC for all users of hormonal 
  contraceptives, since it increases their vulnerability to 
pregnancy significantly for the rest of the cycle. However, if 
users are willing to use back up barrier contraception until 
the next menses, UPA should be recommended.
Thus to help women prevent an unwanted pregnancy after 
unprotected intercourse at any moment during the menstrual 
cycle, a single dose of 30 mg UPA should be recommended 
for use as soon as possible, and no later than 120 hours 
(5 days) after intercourse. If vomiting occurs within 3 hours 
of UPA intake, another tablet should be taken. Pregnancy 
should be excluded before ECP is administered. Further acts 
of unprotected intercourse after ECP use should be avoided 
to prevent the risk of timing a delayed follicular rupture and 
ovulation.
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